Clinical and acoustical variability in hypokinetic dysarthria.
Ten male patients with parkinsonism secondary to Parkinson's disease or progressive supranuclear palsy had clinical neurological, speech, and acoustical speech evaluations. In addition, seven of the patients were evaluated by x-ray computed tomography (CT) and (F-18)-fluorodeoxyglucose (FDG) positron emission tomography (PET). Extensive variability of speech features, both clinical and acoustical, were found and seemed to be independent of the severity of any parkinsonian sign, CT, or FDG PET. In addition, little relationship existed between the variability across each measured speech feature. What appeared to be important for the appearance of abnormal acoustic measures was the degree of overall severity of the dysarthria. These observations suggest that a better understanding of hypokinetic dysarthria may result from more extensive examination of the variability between patients. Emphasizing a specific feature such as rapid speaking rate in characterizing hypokinetic dysarthria focuses on a single and inconstant finding in a complex speech pattern.
D000368:Aged; D003847:Deoxyglucose / Q000031:analogs & derivatives; D004401:Dysarthria / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology*; D005461:Fluorine; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D010302:Parkinson Disease, Secondary / Q000150:complications; D010699:Phonation; D011868:Radioisotopes; D013060:Speech; D013061:Speech Acoustics; D013064:Speech Disorders / Q000503:physiopathology*; D013494:Supranuclear Palsy, Progressive / Q000150:complications; D014055:Tomography, Emission-Computed
D011868:Radioisotopes; D019788:Fluorodeoxyglucose F18; D005461:Fluorine; D003847:Deoxyglucose; D005947:Glucose